Biotech News
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026
Completed Enrollment in LOTUS, a Phase 2b Trial of Zelicapavir in Pediatric Patients with Respiratory Syncytial Virus (RSV); Topline Data Expected in 1Q 2027 Initiated Dosing in RESOLVE, a Phase 2b/3 Trial of Zelicapavir in Adult Patients at High-Risk of Severe RSV Outcomes; Topline Phase 2b Data
